News
Results from the phase 3 VERONA trial were presented at the 2025 Society of Hematologic Oncology Annual Meeting.
In the primary outcome of the VERONA trial, adding venetoclax to azacitidine for the treatment of higher-risk MDS shows no ...
MedPage Today on MSN7d
Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial
"If you have a patient who is young, diploid karyotype plus more than 10% blasts, would you not treat him as AML and move to ...
The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed higher-risk myelodysplastic syndrome, a form of blood cancer known as MDS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback